AT-101 (formerly EP-100)
Multiple cancers overexpressing LHRH receptors (e.g., ovarian, breast, prostate)
Phase 2Active
Key Facts
Indication
Multiple cancers overexpressing LHRH receptors (e.g., ovarian, breast, prostate)
Phase
Phase 2
Status
Active
Company
About A28 Therapeutics
A28 Therapeutics is a private, clinical-stage biotech company founded in 2021 and based in Cambridge, Massachusetts. The company has developed a targeted oncolytic peptide platform, with its lead candidate AT-101 having completed a Phase 2a study demonstrating a promising safety profile and anti-tumor activity. A28's strategy focuses on developing AT-101 as a potential therapy across multiple cancer types and treatment lines, both as a monotherapy and in combination with existing standards of care. The executive team brings decades of combined life sciences experience to advance this novel therapeutic approach.
View full company profile